![Soraya Bekkali](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Soraya Bekkali
Direttore/Membro del Consiglio presso Vedere Bio II, Inc.
Posizioni attive di Soraya Bekkali
Società | Posizione | Inizio | Fine |
---|---|---|---|
Vedere Bio II, Inc.
![]() Vedere Bio II, Inc. Miscellaneous Commercial ServicesCommercial Services Vedere Bio II, Inc. develops ocular gene therapy. The company is based in Cambridge, MA. The company was founded by Cyrus D. Mozayeni. Cyrus D. Mozayeni has been the CEO since incorporation. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Soraya Bekkali
Precedenti posizioni note di Soraya Bekkali
Società | Posizione | Inizio | Fine |
---|---|---|---|
Gyroscope Therapeutics Ltd.
![]() Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Direttore/Membro del Consiglio | - | 01/07/2019 |
Presidente | - | 01/07/2019 | |
LYSOGENE | Direttore Tecnico/Scientifico/R&S | 02/02/2016 | - |
Fovea Pharmaceuticals SA
![]() Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | Direttore Tecnico/Scientifico/R&S | 23/03/2011 | - |
Formazione di Soraya Bekkali
Sorbonne Université | Undergraduate Degree |
Statistiche
Distribuzione geografica
Francia | 4 |
Regno Unito | 2 |
Stati Uniti | 2 |
Posizioni
Chief Tech/Sci/R&D Officer | 2 |
Director/Board Member | 2 |
Undergraduate Degree | 1 |
Settori
Health Technology | 3 |
Commercial Services | 3 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
LYSOGENE | Commercial Services |
Aziende private | 3 |
---|---|
Fovea Pharmaceuticals SA
![]() Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | Health Technology |
Gyroscope Therapeutics Ltd.
![]() Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Vedere Bio II, Inc.
![]() Vedere Bio II, Inc. Miscellaneous Commercial ServicesCommercial Services Vedere Bio II, Inc. develops ocular gene therapy. The company is based in Cambridge, MA. The company was founded by Cyrus D. Mozayeni. Cyrus D. Mozayeni has been the CEO since incorporation. | Commercial Services |
- Borsa valori
- Insiders
- Soraya Bekkali
- Esperienza